TSX Venture: QPT
EDMONTON, Nov. 13 /CNW/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that Dr. Donald Rix, Director of the Company and Chairman of the Board, has passed away. Dr. Rix had been a Director of Quest since September, 2005.
"We are deeply saddened by the passing of Dr. Donald Rix," said Dr. Madi R. Madiyalakan, Chief Executive Officer for Quest. "Dr. Rix was a friend and colleague and a strong believer in Quest. His depth of knowledge, expertise and advice were instrumental in helping Quest to realize its corporate and strategic goals and objectives over the past few years. He will be missed."
The entire Board and staff of Quest wish to express their sincere condolences to Dr. Rix's family.
About Quest PharmaTech Inc.
Quest is a publicly traded, Alberta-based pharmaceutical company committed to the development and commercialization of new pharmaceutical products. It is developing a series of products for the treatment of cancer and dermatological conditions based on its unique photodynamic and sonodynamic therapy platforms.
"Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release."
SOURCE Quest PharmaTech Inc.
For further information: For further information: Dr. Madi R. Madiyalakan, Chief Executive Officer, Quest PharmaTech Inc., Tel: (780) 448-1400 Ext. 204, Email: email@example.com, Internet: www.questpharmatech.com; Media and Investor Relations - Adam Peeler, The Equicom Group Inc., Tel: (416) 815-0700 Ext. 225, E-mail: firstname.lastname@example.org